Hausten Healthcare has entered into an agreement to distribute Snoasis Medical's BioXclude in Japan.
BioXclude is a barrier membrane composed of allograft amnion-chorion tissue which can be used by dental professionals in guided bone and tissue regeneration procedures.
The company said amniotic sac possesses anti-bacterial and anti-microbial properties which help to reduce inflammation at the wound site, and provide a protein-enriched matrix to naturally facilitate epithelialization and improve overall wound healing.
Clinicians may legally import unapproved foreign medical products as BioXclude is not approved for use by the Japanese Ministry of Health and Welfare, for treatment of patients in accordance with the Pharmaceutical Affairs Law.
Snoasis Medical president and founder Robert Tofe said the company is currently seeking regulatory approval in Taiwan and South Korea, and are actively working to set up distribution in China.
"Our relationship with Hausten allows access to Japan, one of the largest dental markets in the world, and punctuates our efforts to set up distribution throughout East Asia," Tofe added.
